These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22877852)

  • 21. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
    Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
    Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
    Doorn JA; Florang VR; Schamp JH; Vanle BC
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
    J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
    Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
    Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
    Lamensdorf I; Eisenhofer G; Harvey-White J; Hayakawa Y; Kirk K; Kopin IJ
    J Neurosci Res; 2000 May; 60(4):552-8. PubMed ID: 10797558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
    J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases.
    Burke WJ; Li SW; Chung HD; Ruggiero DA; Kristal BS; Johnson EM; Lampe P; Kumar VB; Franko M; Williams EA; Zahm DS
    Neurotoxicology; 2004 Jan; 25(1-2):101-15. PubMed ID: 14697885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
    Goldstein DS
    Semin Neurol; 2020 Oct; 40(5):502-514. PubMed ID: 32906170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.
    Jinsmaa Y; Florang VR; Rees JN; Mexas LM; Eckert LL; Allen EM; Anderson DG; Doorn JA
    Chem Biol Interact; 2011 Jun; 192(1-2):118-21. PubMed ID: 21238438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
    Kristal BS; Conway AD; Brown AM; Jain JC; Ulluci PA; Li SW; Burke WJ
    Free Radic Biol Med; 2001 Apr; 30(8):924-31. PubMed ID: 11295535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The catecholaldehyde hypothesis: where MAO fits in.
    Goldstein DS
    J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
    Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ
    Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
    Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.
    Kao CY; Xu M; Wang L; Lin SC; Lee HJ; Duraine L; Bellen HJ; Goldstein DS; Tsai SY; Tsai MJ
    PLoS Genet; 2020 Jun; 16(6):e1008868. PubMed ID: 32579581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
    Werner-Allen JW; DuMond JF; Levine RL; Bax A
    Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
    Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
    PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
    Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
    Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo.
    Vecchio LM; Sullivan P; Dunn AR; Bermejo MK; Fu R; Masoud ST; Gregersen E; Urs NM; Nazari R; Jensen PH; Ramsey A; Goldstein DS; Miller GW; Salahpour A
    J Neurochem; 2021 Aug; 158(4):960-979. PubMed ID: 33991113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
    Mattammal MB; Haring JH; Chung HD; Raghu G; Strong R
    Neurodegeneration; 1995 Sep; 4(3):271-81. PubMed ID: 8581559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.